Personalis to Showcase New Products for Cancer Research and Inherited Disease Testing at ASHG Annual Meeting

October 15, 2014 – Personalis, Inc., a leading genomics-based clinical diagnostic laboratory, announced it will be attending the 2014 American Society of Human Genetics Annual Meeting where it will introduce new products for cancer research and inherited disease testing. The meeting takes place October 18-22 at the San Diego Convention Center.

“Personalis is leading the way in genomic analysis and interpretation in both the research and clinical settings, and we are excited to introduce new services for inherited disease diagnosis and tumor genomic profiling. We are also pleased to support our customers who will be demonstrating their success using our services for genome and exome sequencing and analysis,” said John West, Chief Executive Officer of Personalis.

Those attending the meeting can learn more about the Personalis solutions at the following presentations:

Personalis Genomics Workshop

Sunday, October 19

12:00 – 1:30 PM

Diagnostics and Discovery in Cardiovascular Genomics

Euan Ashley, MRCP, D.Phil (Stanford University)

Analysis of Congenital Disorders Through Trio-based Whole Genome Sequencing

Benjamin D. Solomon, M.D. (Inova Translational Medicine Institute

Advanced Solutions for Complete Profiling of Cancer Samples

Elena Helman, Ph.D. (Personalis)

Personalis Exhibitor Theater

Monday, October 20

1:45 – 2:30 PM

Why Accuracy Matters: Improving Discovery and Diagnostics for Whole Genomes and Exomes

Deanna Church, Ph.D. (Personaiis)

Platform Presentations

Sunday, October 19

2:45 PM: The impact of GRCh38 on clinical sequencing (Session #16)

3:00 PM: Optimized exome sequencing for discovery research: Improved metrics and methods to enhance variant discovery across the biomedical footprint of the genome (Session #16)

3:15 PM: An augmented exome providing accurate structural variant detection (Session #19)

Poster Presentations

Sunday, October 19

5:00 – 6:00 PM: Implementing an augmented clinical exome and reference improvements to enhance diagnostic yield and discovery (2432S)

Monday, October 20

3:00 – 4:00 PM: Accurate detection of low-representation alleles in tumor DNA through augmented exome and transcriptome sequencing (1486M)

3:00 – 4:00 PM: Integrated analysis of transcriptome and exome in cancer samples improves interpretation and reveals additional therapeutic insights (3348M)

Tuesday, October 21

2:00 – 3:00 PM: Using an augmented exome to improve diagnostic yield: case studies in retinal disorders (2943T)

3:00 – 4:00 PM: Method for classifying candidate structural variants into true positives and false positives (582T)

Additionally, attendees can visit Personalis representatives at booth #639 in the exhibit hall, where there will be a series of informative “meet the expert” presentations on various topics. For more information or to register for the workshop visit:

About Personalis, Inc.

Personalis, Inc. ( is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease.  Personalis also provides DNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

Media Contact for Personalis:

Jennifer Havlek